Sonia Guil

2 months ago | nature.com | Daniel Perez-Zsolt |Edurne García-Vidal |Gerardo Ceada |Dàlia Raïch-Regué |Laia Soler |Sonia Guil | +11 more

AbstractPlitidepsin is an antitumoral compound safe for treating COVID-19 that targets the translation elongation factor eEF1A. Here we detect that plitidepsin decreases de novo cap-dependent translation of SARS-CoV-2 and non-viral RNAs but affects less than 13% of the host proteome, thus preserving cellular viability.